Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJR94F
|
|||
| Drug Name |
PMD-026
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Metastatic breast cancer [ICD-11: 2C6Y] | Phase 1 | [1] | |
| Triple negative breast cancer [ICD-11: 2C60-2C65] | Phase 1 | [1] | ||
| Company |
Phoenix Molecular Designs
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ribosomal protein S6 kinase beta-2 (RPS6KB2) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04115306) Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.